Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
MacroGenics pauses work on ADC pending mature survival data
MacroGenics has paused investment in additional opportunities for the ADC until it has updated data from a phase 2 monotherapy prostate cancer trial.
Nick Paul Taylor
Nov 6, 2024 4:44am
Ono inks $700M biobuck deal to bag preclinical LigaChem ADC
Oct 10, 2024 9:40am
AstraZeneca, Daiichi ADC fails to improve breast cancer survival
Sep 23, 2024 7:23am
Merck, Daiichi ADC hits goal in phase 3 lung cancer study
Sep 17, 2024 7:13am
ESMO: AstraZeneca posts data on ADC rivals to AbbVie, Pfizer
Sep 14, 2024 3:00am
AstraZeneca, Daiichi unpack Dato-DXd's overall survival fail
Sep 10, 2024 6:00am
